
    
      Primary

      Evaluate the efficacy and safety of Endostar combined with concurrent chemo-radiotherapy
      (CCRT) in patients with unresectable stage III non-small-cell lung cancer (NSCLC).

      Secondary

      Measure changes in VEGF and other angiogenic cytokines and antiangiogenic factors in plasma
      samples from these patients.

      Evaluate the application of CT perfusion imaging to determine changes in tumor vascular
      mophology and function during treatment.
    
  